Key Takeaways
- 19% Q4 growth, profit flat: Revenue grew ~19% in Q4, with premium products up ~24%, but PAT slipped slightly from ₹142 cr to ₹139 cr on a ~₹9 cr deferred tax provision.
- Raw material costs are biting: Geopolitical supply constraints pushed raw material prices up ~10% or more for crude-linked inputs, forcing two April price increases, the second of which met resistance and required discounting in May.
- Kaeros is the big strategic bet: The fully owned subsidiary, built around a "Dr. Dada" farmer-scientist identity, is positioned as a future-ready agri-science platform and is expected to double sales this fiscal from ~₹110–₹111 cr, eventually contributing 5%–8% of IIL's volume.
- Channel discipline is a structural moat: The company picks up all unsold inventory at season-end rather than leaving it with distributors, reformulates returned material, and manages placements cautiously after last year's dry-crop herbicide returns.
- What to watch next quarter: Whether June monsoons arrive on time to unlock demand, the pace of Kaeros's distributor build-out and sales ramp, and whether a third price increase can stick without further discounting.
Kaeros: The Two-Brand Strategy
- Platform, not a discount fighter: Kaeros carries insecticides, herbicides, fungicides, bio-stimulants, micronutrients and plant health products under a distinct "Dr. Dada" identity portraying a young Indian scientist and farmer's son. Management explicitly stated there is no strategy to compete with lower-grade companies.
- Separate channel, no overlap: Kaeros operates its own distribution network with a policy of zero common distributors between IIL and Kaeros in any area, eliminating channel conflict. Permissions have been obtained across the entire country, and the network is established everywhere except South India.
- Initial discount, then parity or premium: Kaeros products carry a 2%–3% discount initially to gain market position; after that, pricing may be at par with or at a premium to IIL depending on strategy.
- Pack-to-pack ambition: The vision is to eventually run pack-to-pack business through Kaeros, which management sees as more convenient than doing so through the parent.
- Growth trajectory: Kaeros is expected to double sales this fiscal and continue doubling for the next 3–4 years, while IIL grows at a moderate pace.
Rajesh Aggarwal: "IIL is a popular name. IIL has got collaborations, the international collaboration, the products are first coming to IIL. IIL has got its own R&D center. So, the products are first coming to IIL. And Kaeros is a following company."
Demand & Season Outlook
- May is sluggish, June is the hinge: Rising heat across the country has kept May market activity subdued; crop activity is expected to improve as monsoons hit the Indian coastline in June. May should touch last year's numbers but not exceed them; the full quarter's outcome depends on June.
- Herbicides are the growth call: Herbicide contribution was 39% last year but was hit by heavy goods returns and price declines from off-patent launches. Prices have now stabilized and quantities are rising; the segment is expected to register a good increase this year as farmers adopt chemical control over expensive manpower.
- Fungicides crossed into double digits: Fungicide sales reached double-digit contribution in the previous fiscal year.
- B2B holding up: B2B maintained last year's numbers; April showed an increase and May is expected to grow. B2B is expected to be positive for the full year and the current quarter.
- Cautious inventory placement: After last year's dry-spell damage that caused heavy herbicide returns, the company is dividing risk by product and doing limited placements, generating demand first and supplying slowly to ensure material moves through to the farmer by season-end.
Rajesh Aggarwal: "If there is a pull from the market, if there is a demand, if the farmer is coming to buy that product, then only he will get the product. Otherwise, there is a chance that even if a farmer comes to a shop, then he gets the alternate product."
Pricing & Raw Material Pressure
- Two price increases taken, one stuck: The company took price increases in April; the first was well received, the second faced issues and required discounting in May. A decision on a June increase is pending and depends on market demand.
- Raw material costs up sharply: Geopolitical supply-side constraints have pushed raw material prices up ~10% in certain cases, and even higher for crude-linked products. The market is shifting toward a more supplier-driven environment.
- Margin expansion is uncertain: Management declined to quantify margin expansion potential, saying only that there will be a small increase that could become large depending on season, demand and supply.
R&D, Partnerships & New Products
- Partnership launches accelerating: Four products launched through collaborations: Altair from Nissan, plus SPARCLE and Granuvia with Corteva. Two more, SPINOACE and Green Mix, are about to launch.
- In-house R&D products gaining traction: Torry Super, Centran SC, Centran granule, Amuse and others developed through own R&D are receiving excellent farmer response.
- First discovery product nearing filing: The first product discovery with OAT is awaiting an IUPAC name; the entire data pack is ready to be filed in India. A first proposed name was rejected and a second is under review. The product is expected to hit the market in 2027.
- R&D funnel is deep but narrow: Basic discovery screens ~10,000 products per year, yielding about a dozen patents. Formulation development success varies by crop window fit. Reverse engineering carries a relatively high success ratio since the product is already proven.
- New generics added: The company started making carbendazim, pretilachlor, amatrin and propanil, both active ingredient and formulation.
- Nissan pipeline expanding: One product is visible for launch in early kharif next year; one more technology is being signed with Nissan and one more company. The partnership already has seven products with more to join.
Rajesh Aggarwal: "After conducting so many trials, they give me about 10, 15 hardly in the entire year. So that is the type of activity."
Operations & Balance Sheet
- Working capital remains elevated: The working capital cycle is currently 140–150 days; management believes a target of 120 days is achievable, potentially even this year if inventory is liquidated.
- Finance cost reduction targeted: Finance costs are targeted to fall by at least 25%–30%, driven by faster cash collection and lower DSO. Inventory levels were higher last fiscal, and ~₹94 cr was invested in new products from internal accruals.
- Zero channel write-offs: All unsold inventory is picked up from the channel at season-end. If a field pattern fails, the company takes responsibility. Inventory is moved north to south depending on seasonal requirements; anything not consumed within the year is taken back to the factory, reformulated, and brought back to market.
- Technical plants at breakeven: All technical plants have reached breakeven. A new building at Dahej (L&T) has just started manufacturing and is expected to become profitable post-Diwali.
- ICS plots doubling: Insecticides India Crop Solutions plots generated more than ₹30 cr last year on paddy and chili; the program is extending to maize, cotton and other crops with a target to double the number this year.
Rajesh Aggarwal: "We don't take any write-offs in the market. So whatever is left at the end of the season, we pick that up from the channel. We don't leave the inventory with the channel at all because if I leave the inventory, and instead of 5 week on 10, and he is not going to pay to me."
Exports & CDMO
- Exports growing slowly, shifting mix: Exports have been slow but are growing. The business is transitioning from white labelling toward more technicals, with CDMO-type business expected to contribute going forward.
- CDMO in early stages: The company is building its brand to attract CDMO relationships; some small supplies are going out for trial purposes (one container). The pipeline is being built.
- 10% export target: Exports are targeted to grow to 10% of revenue in the next 2–3 years, particularly linked to CDMO.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Kaeros sales | Double total sales from ~₹110–₹111 cr base | FY27 |
| Kaeros volume contribution | Reach 5% to 7%–8% of IIL's volume | FY27 |
| IIL growth | Double-digit growth alongside Kaeros expansion | FY27 |
| Finance cost | Reduce by at least 25%–30% | FY27 |
| Working capital cycle | Reduce to 120 days from 140–150 days | Achievable in FY27 if inventory liquidated |
| ICS plots | Double the number from last year's ~₹30+ cr base | FY27 |
| Premium product mix (Maharatna/Focused Maharatna) | Move from 60%–63% to 60%–70% | Next 3–4 years |
| Exports share | Grow to 10% of revenue | Next 2–3 years |
| First discovery product filing | File in India upon receiving IUPAC name | Expected shortly; product launch in 2027 |
| Sotanala formulation plant | Start operations | Around Diwali (FY27) |
| Sotanala technical plant (first building) | Start operations | March/April 2027 |
| Dahej new building profitability | Turn profitable | Post-Diwali (FY27) |
| Nissan next product launch | Launch in early kharif | Next year (FY28) |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue from operations | ₹2,140 cr (FY26), up ~7% YoY from ₹2,000 cr |
| Q4 revenue growth | ~19% YoY |
| Gross profit | ₹675 cr (FY26), up ~5% YoY from ₹641 cr |
| Gross profit margin | 31.5% (FY26), improved from 23.1% three years ago |
| EBITDA | ₹227 cr (FY26), up ~3% YoY from ₹221 cr |
| EBITDA margin | 10.6% (FY26), improved from 6.8% three years ago |
| PAT | ₹139 cr (FY26), slight decline from ₹142 cr; deferred tax increased by ~₹9 cr |
| ROE | 11.4% (FY26), improved from 6.9% three years ago |
| ROCE | 16.1% (FY26), improved from 10.4% three years ago |
| Q4 volume growth | 5% YoY |
| Q4 value growth | 14% YoY |
| Full-year volume growth | 5% YoY |
| Full-year value growth | 2% YoY |
| Revenue mix (FY26) | B2C 73%, B2B 22%, exports 5% |
| Revenue from patented products | ₹322 cr (FY26), vs ~₹330 cr in FY25 |
| Revenue from combination products | ₹324 cr (FY26), vs ₹311 cr in FY25 |
| Revenue from in-licensing products | ₹226 cr (FY26), vs ₹229 cr in FY25 |
| Revenue from 5 products launched in FY26 | ₹40 cr |
| Revenue from products launched in FY25 | ₹82 cr (FY26), up from ₹23 cr in FY25 |
| Herbicide segment contribution | 39% of total sales (FY26) |
| Premium segment (Maharatna/Focused Maharatna) share | ~60–63% of B2C revenue |
| Exports share | ~5% of total revenue; target to reach 10% in 2–3 years |
| Kaeros revenue | ~₹110–111 cr (FY26), PAT above ₹5 cr |
| Finance cost (consolidated) | ₹16.87 cr (FY26), up from ₹6.86 cr in FY25 |
| Capex guidance | ₹25–30 cr maintenance capex once FY27 projects complete |
| Farmers reached | >75 lakh in FY26 |
| ICS plots planned | >70 for FY27 |
| Field force headcount | >700 sales headquarters, >1,000 brand-building staff, ~1,400 crop advisers at peak |